"description","id","label","name","instanceType","uuid:ID","rationale"
"The main design for the study","StudyDesign_1","","Study Design 1","StudyDesign","a5120e7f-f9fa-44d6-bfd7-a008b4aae05c","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
